The document discusses building a real-time collaborative web tool using operational transformation (OT). OT allows multiple users to collaboratively edit a document by transforming and replicating document operations across clients. The basic concepts covered include the data model, operation model, and OT functions. OT works by having each client execute operations, transmit operations to other clients, and transform operations so that all clients remain in sync despite simultaneous edits. This replicated architecture and use of OT functions helps enable real-time shared editing of documents.
The document outlines a presentation on the lean startup model's relevance to healthcare, emphasizing its application for startups in Singapore. It discusses various macrotrends, the importance of business model innovation alongside scientific advancement, and provides insights on how to mitigate risks through a discovery-driven approach. Key conclusions stress the importance of understanding regulations, customer needs, and financing options early in the innovation process.
Pharmaceutical Mergers Acquisitions in the U.SCapgemini
?
The document analyzes pharmaceutical mergers and acquisitions (M&A) in the U.S., highlighting a significant increase in deal value driven by larger acquisitions since 2014, which contrasts with a predominant number of smaller, product-focused deals. The correlation between new drug approvals and M&A activity is emphasized, noting that one-third of small and mid-sized firms with FDA approvals were acquired shortly after. It suggests that companies need to prepare for potential acquisitions by understanding their market value, the nature of their products, and maintaining strategic relationships.
This document summarizes information about prescription drug costs and development. It discusses how medicines have transformed treatment for diseases like hepatitis C and cancer. Developing new treatments takes over 10 years and $2.6 billion on average, with only 12% of drug candidates being approved. Medicines help avoid expensive medical services and provide major savings to the healthcare system. While drug costs have risen, they account for a stable share of overall healthcare spending and are projected to grow in line with other healthcare costs. Many factors influence drug prices, including discounts, rebates, and competition from generics.
The document discusses building a real-time collaborative web tool using operational transformation (OT). OT allows multiple users to collaboratively edit a document by transforming and replicating document operations across clients. The basic concepts covered include the data model, operation model, and OT functions. OT works by having each client execute operations, transmit operations to other clients, and transform operations so that all clients remain in sync despite simultaneous edits. This replicated architecture and use of OT functions helps enable real-time shared editing of documents.
The document outlines a presentation on the lean startup model's relevance to healthcare, emphasizing its application for startups in Singapore. It discusses various macrotrends, the importance of business model innovation alongside scientific advancement, and provides insights on how to mitigate risks through a discovery-driven approach. Key conclusions stress the importance of understanding regulations, customer needs, and financing options early in the innovation process.
Pharmaceutical Mergers Acquisitions in the U.SCapgemini
?
The document analyzes pharmaceutical mergers and acquisitions (M&A) in the U.S., highlighting a significant increase in deal value driven by larger acquisitions since 2014, which contrasts with a predominant number of smaller, product-focused deals. The correlation between new drug approvals and M&A activity is emphasized, noting that one-third of small and mid-sized firms with FDA approvals were acquired shortly after. It suggests that companies need to prepare for potential acquisitions by understanding their market value, the nature of their products, and maintaining strategic relationships.
This document summarizes information about prescription drug costs and development. It discusses how medicines have transformed treatment for diseases like hepatitis C and cancer. Developing new treatments takes over 10 years and $2.6 billion on average, with only 12% of drug candidates being approved. Medicines help avoid expensive medical services and provide major savings to the healthcare system. While drug costs have risen, they account for a stable share of overall healthcare spending and are projected to grow in line with other healthcare costs. Many factors influence drug prices, including discounts, rebates, and competition from generics.